Status:

RECRUITING

Repertoire and Properties of Anti-drug Antibodies Involved in Immediate Hypersensitivity in the Operating Room

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Collaborating Sponsors:

Institut Pasteur

Conditions:

Hypersensitivity, Immediate

Peri-operative Injury

Eligibility:

All Genders

18-70 years

Phase:

NA

Brief Summary

Acute per-anesthetic hypersensitivity reaction (HSA-PA) is a rapidly occurring systemic reaction following injection of a drug during anesthesia (mortality between 3 and 9%). The substances responsibl...

Detailed Description

Acute per-anesthetic hypersensitivity reaction (HSA-PA) is a rapidly occurring systemic reaction following injection of a drug during anesthesia (mortality between 3 and 9%). The substances responsibl...

Eligibility Criteria

Inclusion

  • Common to both groups:
  • Age ≥ 18 years old and ≤ 70 years old
  • Patient having presented an allergic reaction in the operating room in the last 10 years, regardless of the grade of severity, the causative agent or the type of anesthesia
  • Patient having benefited from an allergy-anaesthesia consultation in the investigator center
  • For IgE group:
  • \- presence of at least one positive skin test to one of the suspected agent (curare and/or antibiotic) during the allergist consultation
  • For the IgG group:
  • \- presence of circulating IgG-type antibodies directed against one of the suspected agents (curare, antibiotic, antiseptic), identified in the routine biological tests carried out at the time of the shock and / or the consultation of allergology.

Exclusion

  • Common to both groups:
  • Absence of written informed consent
  • Protected person: under guardianship or curatorship
  • Patient without social security
  • Pregnancy of breast feeding
  • Ongoing immunosuppressive or chemotherapy
  • Acute heart failure
  • Patient included in another interventional research with an exclusion period
  • For IgE group:
  • Taking oral or injectable anticoagulants
  • Taking a double antiplatelet aggregation
  • Previous sternotomy
  • Previous thoracic radiation therapy
  • Known allergy to local anesthesic or iodinated skin products
  • Previous major sternal cutaneous lesions
  • Prerequisites for carrying out the sternal sample in order to carry out a myelogram (IgE group):
  • Leukocytes \> 4 giga/L in the 2 months preceding inclusion
  • Platelets \> 100,000 / mm3 in the 2 months preceding inclusion
  • For the IgG group
  • Orthostatic hypotension
  • Realization of a blood donation in the 6 to 8 weeks preceding inclusion
  • Prerequisites for performing the blood sample (IgG group):
  • \- Hemoglobin \> 12.5 g/dL for women and \> 13 g/dL for men in the 2 months preceding inclusion

Key Trial Info

Start Date :

April 12 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 15 2033

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT05420935

Start Date

April 12 2023

End Date

December 15 2033

Last Update

September 19 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hôpital Bichat claude Bernard

Paris, Paris, France, 75018